PMLiVE5d
How women are revolutionising rare disease
Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges ...
PMLiVE11d
The partnership triangle
Many initiatives have tried to address this partnership challenge: the Healthcare Communications Association’s (HCA) own ...
PMLiVE4d
J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study
Johnson & Johnson (J&J) and Legend Biotech have shared positive long-term results for their BCMA-directed T-cell ...
PMLiVE5d
Gaps in obesity care and education
Yesterday marked World Heart Day, and Medscape is at the forefront with a featured article in Media Planet's cardiology ...
PMLiVE4d
Successful Education at ESC
Medscape wants to take the opportunity to look back and recap what was accomplished at ESC 2024. At this year’s event, ...
PMLiVE5d
‘Causes That Count, Health’ report – key issues affecting global health
Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people ...
PMLiVE5d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission ...
PMLiVE4d
FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients
The US Food and Drug Administration (FDA) has approved IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms ...
PMLiVE6d
Ipsen’s Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome
Ipsen’s Kayfanda (odevixibat) has been approved by the European Commission (EC) under exceptional circumstances to treat ...
PMLiVE9d
Supporting Blood Cancer Patients: The Importance of Patient-Centric Pharma Campaigns
This Blood Cancer Awareness Month, we want to highlight the critical role of patient-centricity in building awareness, ...
PMLiVE4d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
PMLiVE9d
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...